Search

Novavax Inc

Gesloten

SectorGezondheidszorg

7.94 2.72

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.58

Max

8.07

Belangrijke statistieken

By Trading Economics

Inkomsten

-27M

-9.5M

Verkoop

-7.6M

140M

K/W

Sectorgemiddelde

3.112

68.51

EPS

-0.06

Winstmarge

-6.803

Werknemers

749

EBITDA

-29M

-543K

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+71.19% upside

Dividenden

By Acuity

Volgende Winsten

5 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-102M

1.2B

Vorige openingsprijs

5.22

Vorige sluitingsprijs

7.94

Novavax Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2026, 19:36 UTC

News

Novavax Inc shares are higher today, supported by $57 million in second-quarter revenue and ongoing discussions with Sanofi on a COVID-19/influenza vaccine.

6 aug 2026, 23:01 UTC

News

Novavax Inc expects 2026 revenue of $235 million to $275 million. Shares are trading higher in after-market hours following the earnings call.

5 aug 2026, 23:01 UTC

Novavax shares are higher in after-market trading, though they remain below the 20-day moving average amid weaker-than-expected U.S. job growth data.

4 aug 2026, 23:36 UTC

Novavax Inc. shares are higher in after-market trading, despite remaining below their 20-day moving average. Broader market sentiment may support this upward movement.

3 aug 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

31 jul 2026, 19:16 UTC

Novavax Inc. shares are lower today, reflecting a decline from Thursday's close amid rising bond yields and crude oil prices contributing to inflation concerns.

30 jul 2026, 22:01 UTC

Novavax Inc. shares advanced in after-market trading, rebounding from earlier session lows, though they remain below the 20-day moving average.

29 jul 2026, 23:06 UTC

Novavax Inc. shares are higher in after-market trading, gaining slightly since Wednesday's close, despite broader market weakness and significant declines over the past month.

28 jul 2026, 16:06 UTC

Novavax Inc. shares are lower today, reflecting broader market declines amid investor caution ahead of earnings and the Federal Reserve's interest rate decision.

27 jul 2026, 14:02 UTC

Novavax Inc shares are higher in pre-market trading, rising to $7.73. This increase occurs amid three consecutive lower session closes and mixed economic data.

24 jul 2026, 18:46 UTC

Novavax Inc. shares are lower today, continuing a trend of declines following three consecutive sessions of lower closes and trading below the 20-day moving average.

23 jul 2026, 09:01 UTC

Novavax Inc shares are higher in pre-market trading, reflecting upward momentum since Wednesday. Broader market sentiment remains positive amid rising Asian equity indices.

22 jul 2026, 23:11 UTC

Novavax Inc. shares are higher in after-market hours, driven by strength in biotechnology stocks. The company remains below its 20-day moving average.

21 jul 2026, 22:46 UTC

Novavax Inc. shares declined in after-market trading, remaining below their 20-day moving average despite a broader market rebound in the tech sector.

20 jul 2026, 23:46 UTC

Novavax Inc. shares traded roughly flat after-market with no specific news identified. The stock remains significantly below its 20-day moving average.

Peer Vergelijking

Prijswijziging

Novavax Inc Prognose

Koersdoel

By TipRanks

71.19% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.25 USD  71.19%

Hoogste 19 USD

Laagste 7 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novavax Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

2

Buy

1

Hold

1

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat